Show simple item record

dc.contributor.authorAndersen, Karl
dc.date.accessioned2014-02-05T16:44:21Z
dc.date.available2014-02-05T16:44:21Z
dc.date.issued2013
dc.identifier.citationCurr. Hypertens. Rep. 2013, 15 (5):484-8en
dc.identifier.issn1534-3111
dc.identifier.pmid23917810
dc.identifier.doi10.1007/s11906-013-0379-7
dc.identifier.urihttp://hdl.handle.net/2336/312288
dc.description.abstractHypertension is an established risk factor for stroke, premature coronary artery disease and heart failure. Control of elevated blood pressure has been shown to result in significant reduction of cardiovascular risk. Aldosterone, the final product of the renin-angiotensin-aldosterone system (RAAS), not only causes salt and water reabsorbtion in the kidneys through its effect on the mineralocorticoid hormone receptor (MR), but also an MR-independent effect, not regulated by conventional MR blockade. Although many pharmacological agents target different levels of the RAAS cascade, these generally result in elevated renin concentration and plasma renin activity. This upstream feedback response subsequently results in elevated levels of angiotensin II, a potent vasoconstrictor and stimulus to aldosterone release. This aldosterone breakthrough counteracts the long-term blood pressure-lowering effect of these agents. Therefore the development of a new class of pharmacologic agents that directly inhibit the production of aldosterone may prove clinically useful in reducing aldosterone and thereby controlling elevated blood pressure.
dc.language.isoenen
dc.publisherSpringeren
dc.relation.urlhttp://link.springer.com/article/10.1007/s11906-013-0379-7#page-1en
dc.relation.urlhttp://dx.doi.org/10.1007/s11906-013-0379-7
dc.rightsArchived with thanks to Current hypertension reportsen
dc.subjectHáþrýstinguren
dc.subject.meshAldosterone Synthaseen
dc.subject.meshHypertensionen
dc.titleAldosterone synthase inhibition in hypertension.en
dc.typeArticleen
dc.contributor.departmentLandspitali Univ Hosp Iceland, Cardiovasc Res Ctr, IS-101 Reykjavik, Icelanden
dc.identifier.journalCurrent hypertension reportsen
html.description.abstractHypertension is an established risk factor for stroke, premature coronary artery disease and heart failure. Control of elevated blood pressure has been shown to result in significant reduction of cardiovascular risk. Aldosterone, the final product of the renin-angiotensin-aldosterone system (RAAS), not only causes salt and water reabsorbtion in the kidneys through its effect on the mineralocorticoid hormone receptor (MR), but also an MR-independent effect, not regulated by conventional MR blockade. Although many pharmacological agents target different levels of the RAAS cascade, these generally result in elevated renin concentration and plasma renin activity. This upstream feedback response subsequently results in elevated levels of angiotensin II, a potent vasoconstrictor and stimulus to aldosterone release. This aldosterone breakthrough counteracts the long-term blood pressure-lowering effect of these agents. Therefore the development of a new class of pharmacologic agents that directly inhibit the production of aldosterone may prove clinically useful in reducing aldosterone and thereby controlling elevated blood pressure.


This item appears in the following Collection(s)

Show simple item record